PMID- 30511255
OWN - NLM
STAT- MEDLINE
DCOM- 20190403
LR  - 20200225
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Linking)
VI  - 28
IP  - 3
DP  - 2019 Mar
TI  - Determining clinically important differences in health-related quality of life in 
      older patients with cancer undergoing chemotherapy or surgery.
PG  - 663-676
LID - 10.1007/s11136-018-2062-6 [doi]
AB  - PURPOSE: Using the EORTC Global Health Status (GHS) scale, we aimed to determine 
      minimal clinically important differences (MCID) in health-related quality of life 
      (HRQOL) changes for older cancer patients with a geriatric risk profile, as 
      defined by the geriatric 8 (G8) health screening tool, undergoing treatment. 
      Simultaneously, we assessed baseline patient characteristics prognostic for HRQOL 
      changes. METHODS: Our analysis included 1424 (G8 </= 14) older patients with cancer 
      scheduled to receive chemotherapy (n = 683) or surgery (n = 741). Anchor-based 
      methods, linking the GHS score to clinical indicators, were used to determine 
      MCID between baseline and follow-up at 3 months. A threshold of 0.2 standard 
      deviation (SD) was used to exclude MCID estimates too small for interpretation. 
      Logistic regressions analysed baseline patient characteristics prognostic for 
      HRQOL changes. RESULTS: The 15-item Geriatric Depression Scale (GDS15), Visual 
      Analogue Scale (VAS) for Fatigue and ECOG Performance Status (PS) were selected 
      as clinical anchors. In the surgery group, MCID estimates for improvement and 
      deterioration were ECOG PS (5*, 11*), GDS15 (5*, 2) and VAS Fatigue (3, 9*). In 
      the chemotherapy group, MCID estimates for improvement and deterioration were 
      ECOG PS (8*, 7*), GDS15 (5, 4) and VAS Fatigue (5, 5*). Estimates with * were 
      > 0.2 SD threshold. Patients experiencing pain or malnutrition (surgery group) or 
      fatigue (chemotherapy group) at baseline showed a significantly stable or 
      improved HRQOL (p < 0.05) after their treatment. CONCLUSION: The reported MCID 
      for improvement and deterioration depended on the anchor used and treatment 
      received. The estimates can be used to evaluate significant changes in HRQOL and 
      to determine sample sizes in clinical trials.
FAU - Quinten, C
AU  - Quinten C
AUID- ORCID: 0000-0003-2691-2326
AD  - Laboratory of Experimental Oncology (LEO), Department of Oncology, KU Leuven, 
      Leuven, Belgium. chantal.quinten@kuleuven.be.
AD  - Department of General Medical Oncology and Geriatric Medicine, University 
      Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. 
      chantal.quinten@kuleuven.be.
FAU - Kenis, C
AU  - Kenis C
AD  - Department of General Medical Oncology, University Hospitals Leuven, Leuven, 
      Belgium.
AD  - Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium.
FAU - Decoster, L
AU  - Decoster L
AD  - Department of Medical Oncology, Oncologisch Centrum, Universitair Ziekenhuis 
      Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
FAU - Debruyne, P R
AU  - Debruyne PR
AD  - Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium & Positive Ageing 
      Research Institute (PARI), Anglia Ruskin University, Chelmsford, UK.
FAU - De Groof, I
AU  - De Groof I
AD  - Department of Geriatric Medicine, Iridium Cancer Network Antwerp, St. Augustinus, 
      Wilrijk, Belgium.
FAU - Focan, C
AU  - Focan C
AD  - Department of Oncology, Clinique Saint-Joseph, CHC-Liege Hospital Group, Liege, 
      Belgium.
FAU - Cornelis, F
AU  - Cornelis F
AD  - Department of Medical Oncology, Cliniques Universitaires Saint-Luc, UCL, 
      Brussels, Belgium.
FAU - Verschaeve, V
AU  - Verschaeve V
AD  - Department of Medical Oncology, GHDC Grand Hopital de Charleroi, Charleroi, 
      Belgium.
FAU - Bachmann, C
AU  - Bachmann C
AD  - Department of Geriatric Medicine, AZ Sint-Lucas, Ghent, Belgium.
FAU - Bron, D
AU  - Bron D
AD  - Department of Hematology, ULB Institut Jules Bordet, Brussels, Belgium.
FAU - Luce, S
AU  - Luce S
AD  - Department Medical Oncology, University Hospital Erasme, Universite Libre de 
      Bruxelles (ULB), Brussels, Belgium.
FAU - Debugne, G
AU  - Debugne G
AD  - Department of Geriatric Medicine, Centre Hospitalier de Mouscron, Mouscron, 
      Belgium.
FAU - Van den Bulck, H
AU  - Van den Bulck H
AD  - Department of Medical Oncology, Imelda Hospital, Bonheiden, Belgium.
FAU - Goeminne, J C
AU  - Goeminne JC
AD  - Department of Medical Oncology, CHU-UCL-Namur, site Sainte-Elisabeth, Namur, 
      Belgium.
FAU - Baitar, A
AU  - Baitar A
AD  - Department of Medical Oncology, ZNA Middelheim, Antwerp, Belgium.
FAU - Geboers, K
AU  - Geboers K
AD  - Centre for Oncology and Hematology, AZ Turnhout, Turnhout, Belgium.
FAU - Petit, B
AU  - Petit B
AD  - Department of Medical Oncology, Centre Hospitalier Jolimon, La Louviere, Belgium.
FAU - Langenaeken, C
AU  - Langenaeken C
AD  - Department of Medical Oncology, Iridium Cancer Network Antwerp, AZ Klina, 
      Brasschaat, Belgium.
FAU - Van Rijswijk, R
AU  - Van Rijswijk R
AD  - Department of Medical Oncology, ZNA Stuivenberg, Antwerp, Belgium.
FAU - Specenier, P
AU  - Specenier P
AD  - Department of Medical Oncology, University Hospital Antwerp, Antwerp, Belgium.
FAU - Jerusalem, G
AU  - Jerusalem G
AD  - Department of Medical Oncology, Centre Hospitalier Universitaire Sart Tilman and 
      Liege University, Liege, Belgium.
FAU - Praet, J P
AU  - Praet JP
AD  - Department of Geriatric Medicine, CHU St-Pierre, Free Universities Brussels, 
      Brussels, Belgium.
FAU - Vandenborre, K
AU  - Vandenborre K
AD  - Department of Medical Oncology, AZ Vesalius, Tongeren, Belgium.
FAU - Lycke, M
AU  - Lycke M
AD  - Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium & Positive Ageing 
      Research Institute (PARI), Anglia Ruskin University, Chelmsford, UK.
FAU - Flamaing, J
AU  - Flamaing J
AD  - Department of General Medical Oncology, University Hospitals Leuven, Leuven, 
      Belgium.
AD  - Department of Chronic Diseases, Metabolism and Ageing - CHROMETA, KU Leuven, 
      Leuven, Belgium.
FAU - Milisen, K
AU  - Milisen K
AD  - Department of Geriatric Medicine, University Hospitals Leuven, Leuven, Belgium.
AD  - Department of Public Health and Primary Care, Academic Centre for Nursing and 
      Midwifery, KU Leuven, Leuven, Belgium.
FAU - Lobelle, J P
AU  - Lobelle JP
AD  - , Beernem, Belgium.
FAU - Wildiers, H
AU  - Wildiers H
AD  - Department of General Medical Oncology, University Hospitals Leuven, Leuven, 
      Belgium.
AD  - Department of Oncology, KU Leuven, Leuven, Belgium.
LA  - eng
GR  - PC_24_A-025/Cancer Plan/
GR  - Fonds voor Wetenschappelijk Onderzoek/180211N/
PT  - Journal Article
DEP - 20181203
PL  - Netherlands
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of 
      treatment, care and rehabilitation
JID - 9210257
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Female
MH  - Geriatric Assessment/*methods
MH  - *Health Status
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - Neoplasms/*therapy
MH  - Pain/pathology
MH  - Pain Measurement/methods
MH  - Quality of Life/*psychology
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Cancer
OT  - Elderly patients with cancer
OT  - Geriatric assessment
OT  - Minimal important differences
OT  - Quality of life
EDAT- 2018/12/05 06:00
MHDA- 2019/04/04 06:00
CRDT- 2018/12/05 06:00
PHST- 2018/11/22 00:00 [accepted]
PHST- 2018/12/05 06:00 [pubmed]
PHST- 2019/04/04 06:00 [medline]
PHST- 2018/12/05 06:00 [entrez]
AID - 10.1007/s11136-018-2062-6 [pii]
AID - 10.1007/s11136-018-2062-6 [doi]
PST - ppublish
SO  - Qual Life Res. 2019 Mar;28(3):663-676. doi: 10.1007/s11136-018-2062-6. Epub 2018 
      Dec 3.